Can You Switch from Xarelto to Pradaxa?
Yes, you can switch from rivaroxaban (Xarelto) to dabigatran (Pradaxa), and the transition is straightforward: simply start Pradaxa at the time of your next scheduled Xarelto dose. Both are approved direct oral anticoagulants (DOACs) for stroke prevention in atrial fibrillation and venous thromboembolism treatment 1, 2.
How to Make the Switch
Start dabigatran at the exact time you would have taken your next rivaroxaban dose 3. There is no need for:
- Bridging with heparin
- Waiting periods between medications
- Overlap of the two drugs
- Laboratory monitoring during the transition 4
The pharmacokinetic data demonstrate that switching at the next scheduled dose maintains appropriate anticoagulation without gaps or excessive overlap 3.
Critical Considerations Before Switching
Renal Function Assessment
Your kidney function determines whether dabigatran is appropriate:
- CrCl >50 mL/min: Dabigatran 150 mg twice daily is standard 5
- CrCl 30-50 mL/min: Reduce to dabigatran 110 mg twice daily or 75 mg twice daily (depending on indication) 6, 5
- CrCl <30 mL/min: Dabigatran is contraindicated - stay on rivaroxaban instead 6, 5
This is crucial because dabigatran has 80% renal elimination compared to rivaroxaban's 33% 6. Check your creatinine clearance before switching - this is non-negotiable.
Age Considerations
- Age ≥75 years: Consider dabigatran 110 mg twice daily due to better bleeding/efficacy balance 7
- Age ≥80 years: Dabigatran 110 mg twice daily is preferred 4
Drug Interactions
Avoid dabigatran if you're taking strong P-glycoprotein inhibitors with moderate renal impairment:
Why You Might Switch
Valid reasons include:
- Once-daily dosing preference (rivaroxaban) vs. twice-daily (dabigatran) - though you're going the opposite direction
- Gastrointestinal side effects: Dabigatran causes more dyspepsia (11.8% vs 5.8% with warfarin) 7, 5
- Bleeding profile differences: Dabigatran has lower intracranial bleeding but higher GI bleeding risk in patients ≥75 years 8
- Renal function changes: Rivaroxaban is safer with declining kidney function 6
Safety Data on Switching
Real-world registry data from 716 patients switching between anticoagulants showed:
- Major bleeding at 30 days: 0.3% (95% CI 0.0-1.0)
- Major cardiovascular events: 0.8% (95% CI 0.3-1.8)
- Overall bleeding rate: 12.2% 9
The switch itself does not increase bleeding or thrombotic risk when done correctly 3, 9.
Common Pitfalls to Avoid
Don't double up doses: If you miss the transition timing, take dabigatran as soon as possible but skip if <6 hours before next dose 5
Don't open the capsules: Dabigatran must be swallowed whole - breaking capsules increases exposure by 75% 5
Storage matters: Once opened, use dabigatran within 4 months; keep in original bottle (moisture sensitive) 5
Don't assume equivalence: Dabigatran requires twice-daily dosing - missing doses creates anticoagulation gaps due to its 12-17 hour half-life 2
When NOT to Switch
Stay on rivaroxaban if you have:
- CrCl <30 mL/min (dabigatran contraindicated)
- Difficulty with twice-daily dosing adherence
- History of dyspepsia or GI intolerance
- Severe liver disease (Child-Pugh B or C) 6
Monitoring After the Switch
- No routine coagulation monitoring needed for dose adjustments 5
- Recheck renal function at least annually, more frequently if CrCl 30-50 mL/min 8, 7
- Watch for signs of bleeding or dyspepsia in first weeks 5
The evidence supports that switching between DOACs at the next scheduled dose is safe and maintains anticoagulation status without increased risk 3, 9. However, the decision should account for your specific renal function, age, and ability to adhere to twice-daily dosing.